RAGE axis: Animal models and novel insights into the vascular complications of diabetes

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 8, 2004, Pages 1342-1349

  Naka, Yoshifumi ^a   Bucciarelli, Loredana G ^a   Wendt, Thoralf ^a   Lee, Larisse K ^a   Ling, Ling Rong ^a   Ramasamy, Ravichandran ^a   Shi, Fang Yan ^a   Schmidt, Ann Marie ^a  

^a Columbia University ^*  (United States)

Author keywords

Animal models; Diabetes; Inflammation; Receptors; Signal transduction

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; APOLIPOPROTEIN E; BROXURIDINE; CITRIC ACID; ESTRADIOL; LOW DENSITY LIPOPROTEIN RECEPTOR; PERINDOPRIL; ROSIGLITAZONE; SERUM ALBUMIN; STREPTOZOCIN; TROGLITAZONE;

ANIMAL MODEL; ARTERY INJURY; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL INJURY; BLOOD VESSEL WALL; CELL ACTIVATION; CELL INFILTRATION; EXPERIMENTAL DIABETES MELLITUS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RECEPTOR BLOCKING; RESTENOSIS; SHORT SURVEY; SIGNAL TRANSDUCTION; VESSEL;

ANIMALS; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; CELL ADHESION MOLECULES; CORONARY RESTENOSIS; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; GLYCOSYLATION END PRODUCTS, ADVANCED; HYPERLIPIDEMIAS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, ANIMAL; OXIDATIVE STRESS; RATS; RATS, ZUCKER; RECEPTORS, IMMUNOLOGIC; SIGNAL TRANSDUCTION; SOLUBILITY; VASCULITIS;

EID: 3943061592     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000133191.71196.90     Document Type: Short Survey

References (58)

1. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J, Esposito C, Hegarty H, Hurley W, Clauss M, Wang F, Pan YC, Tsang TC, Stern D. Isolation and characterization of binding proteins for advanced glycosylation end products from lung tissue which are present on the endothelial cell surface. J Biol Chem. 1992;267:14987-14997.
2. Neeper M, Schmidt AM, Brett J, Yan SD, Wang F, Pan YC, Elliston K, Stern D, Shaw A. Cloning and expression of RAGE: a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem. 1992;267:14998-15004.
3. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slattery T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/cal granulin polypeptides. Cell. 1999;97:889-901.
4. Hori O, Brett J, Slattery T, Cao R, Zhang J, Chen J, Nagashima M, Nitecki D, Morser J, Stern D, Schmidt AM. RAGE is a cellular binding site for amphoterin: mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system. J Biol Chem. 1995;270:25752-25761.
5. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, Tanji N, Lu Y, Lalla E, Fu C, Hofmann MA, Kislinger T, Ingram M, Lu A, Tanaka H, Hori O, Ogawa S, Stern DM, Schmidt AM. Blockade of amphoterin/RAGE signaling suppresses tumor growth and metastases. Nature. 2000;405:354-360.
6. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Nagashima M, Morser J, Migheli A, Nawroth P, Godman G, Stern D, Schmidt AM. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature. 1996;382:685-691,
7. Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, Yu J, Soto C, Schmidt AM, Stern D, Kindy M. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nature Medicine. 2000; 6:643-651.
8. Chavakis T, Bierhaus A, Al-Fakhri N, Schneider D, Witte S, Linn T, Nagashima M, Morser J, Arnold B, Preissner KT, Nawroth PP. The Pattern Recognition Receptor (RAGE) is a counterreceptor for leukocyte integrins: a novel pathway for inflammatory cell recruitment. J Exp Med. 2003;198:1507-1515.
9. Kislinger T, Fu C, Huber B, Qu W, Taguchi A, Yan SD, Hofmann M, Yan SF, Pischetsrider M, Stern D, Schmidt AM. Nε (carboxymethyl)lysine modifications of proteins are ligands for RAGE that activate cell signaling pathways and modulate gene expression. J Biol Chem. 1999; 274:31740-31749.
10. Anderson MM, Requena JR, Crowley JR, Thorpe SR, Heinecke J. The myeloperoxidase system of human phagocytes generates Nε-(carboxymethyl) lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation, J Clin Invest. 1999;104:103-113.
11. Nagai R, Unno Y, Hayashi MC, Masuda S, Hayase F, Kinae N, Horiuchi S. Peroxynitrite induces formation of N(ε)-(carboxymethyl)lysine by the cleavage of Amadori product and generation of glucosone and glyoxal from glucose: novel pathways for protein modification by peroxynitrite. Diabetes. 2002;51:2833-2839.
12. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care 1992;1835-1843.
13. Niwa T. 3-deoxyglucosone metabolism, analysis, biological activity, and clinical implication. J Chromat Biomed Sci Appl. 1999;731:23-36.
14. Hasuike Y, Nakanishi T, Otaki Y, Nanami M, Tanimoto T, Taniguchi N, Takamitsu Y. Plasma 3-deoxyglucosone elevation in chronic renal failure is associated with increased aldose reductase in erythrocytes. Am J Kid Dis. 2002;40:464-471.
15. Hamada Y, Nakamura J, Naurse K, Komori T, Kato K, Kasuya Y, Nagai R, Hotta N. Epalrestat, an aldose reductase inhibitor, reduces the levels of CML protein adducts and their precursors in erythrocytes from diabetic patients. Diabetes Care. 2000;23:1539-1544.
16. Wang H, Bloom O, Zhang M, Vishnuhakat JM, Ombrellino M, Che J, Frazier A, Yang H, Ivanova S, Borovikova L, Manogue KR, Faist E, Abraham E, Andersson J, Andersson U, Molina PE, Abumrad NN, Sama A, Tracey KJ. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 1999;285:248-251.
17. Rammes A, Roth J, Goebeler M, Klempt M, Hartmann M, Sorg C. Myeloid-related protein (MRP) 8 and MRP14, calcium-binding proteins of the S100 family, are secreted by activated monocytes via a novel, tubulin-dependent pathway. J Biol Chem. 1997;272:9496-9502.
18. Frosch M, Strey A, Vogl T, Wulffraat NM, Kuis W, Sunderkotter C, Harms E, Sorg C, Roth J. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum. 2000; 43:628-637.
19. King H, Aubert R, Herman W. Global burden of diabetes, 1995-2005. Prevalence, numerical estimates and projections. Diabetes Care. 1998; 21:1414-1431.
20. Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen E, Pyorala K. Five-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and non-diabetic subjects. Circ. 1990;82:27-36.
21. Manson JE, Colditz GA, Stampfer MJ, Willett WC, Krolewski AS, Rosner B, Arky RA, Speizer FE, Hennekens CH. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med. 1991;151:1141-1147.
22. Kannel WB, McGee DL. Diabetes and cardiovascular disease: The Framingham Study. JAMA. 1979;241:2035-2038.
23. Ritthaler U, Deng Y, Zhang Y, Greten J, Abel M, Allenberg J, Otto G, Roth H, Bierhaus A, Ziegler R, Schmidt AM, Waldherr R, Wahl P, Stern D, Nawroth P. Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am J Pathol. 1995;146: 688-694.
24. Cipollone F, lezzi A, Fazia M, Zucchelli M, Pini B, Cuccurullo C, De Cesare D, De Blasis G, Muraro R, Bei R, Chiarelli F, Schmidt AM, Cuccurullo F, Mezzetti A. The Receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circ. 2003;108:1070-1077.
25. Kunjathoor VV, Wilson DL, LeBoeuf RC. Increased atherosclerosis in streptozotocin-induced diabetic mice. J Clin Invest. 1996;97:1767-1773.
26. Zhang S, Reddick RL, Piedrahita JA, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 1992;258:468-471.
27. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992;71:343-353.
28. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb. 1994;14:133-140.
29. Like AA, Rossini AA. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science. 1976;193:415-417.
30. Park L, Raman KG, Lee KJ, Yan L, Ferran LJ, Chow WS, Stern D, Schmidt AM. Suppression of accelerated diabetic atherosclerosis by soluble Receptor for AGE (sRAGE). Nat Med. 1998;4:1025-1031.
31. Kislinger T, Tanji N, Wendt T, Qu W, Lu Y, Ferran LJ, Jr., Taguchi A, Olson K, Bucciarelli L, Goova M, Hofmann MA, Cataldegirmen G, D'Agati V, Pischetsrieder M, Stern DM, Schmidt AM. RAGE mediates inflammation and enhanced expression of tissue factor in the vasculature of diabetic apolipoprotein E null mice. Arterio Thromb Vasc Biol. 2001; 21:905-910.
32. Wautier JL, Zoukourian C, Chappey O, Wautier MP, Guillausseau PJ, Cao R, Hori O, Stern D, Schmidt AM. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: soluble receptor for advanced glycation endproducts blocks hyperpermeability. J Clin Invest. 1996;97: 238-243.
33. Morel DW, Chisolm GM. Antioxidant treatment of diabetic rats inhibits lipoprotein oxidation and cytotoxicity. J Lipid Res. 1989;30:1827-1834.
34. Bucciarelli LG, Wendt T, Qu W, Lu Y, Lalla E, Rong LL, Goova MT, Moser B, Kislinger TK, Lee DC, Kashyap Y, Stern DM, Schmidt AM. RAGE blockade stabilizes established atherosclerosis in diabetic apoli-poprotein E null mice. Circ. 2002;106:2827-2835.
35. Lee KJ, Lu Y, Ginsberg MD, Ferran LJ, Stern DM, Schmidt AM. A murine model of accelerated atherosclerosis in diabetic LDL Receptor deficient mice. Circ (Suppl). 1997;96:I-175.
36. Reaven P, Merat S, Casanada F, Sutphin M, Palinski W. Effect of streptozotocin-induced hyperglycemia on lipid profiles, formation of advanced glycation endproducts in lesions, and extent of atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 1997; 17:2250-2256.
37. Wendt TM., Bucciarelli L.G., Lu Y., Qu W., Fan L, Tsai M., Ferran LJ, Stern DM, Schmidt AM. Accelerated atherosclerosis and vascular inflammation develop in apo E null mice with type 2 diabetes. Circ (Suppl). 2000;102:II-231.
38. Lin RY, Choudhury RP, Cai W, Lu M, Fallon JT, Fisher EA, Vlassara H. Dietary glycotoxins promote diabetic atherosclerosis in apolipoprotein E-deficient mice. Atherosclerosis. 2003;168:213-220.
39. Levi Z, Shaish A, Yacov N, Levkovitz H, Trestman S, Gerber Y, Cohen H, Dvir A, Rhachmani R, Ravid M, Harats D. Rosiglitazone (PPAR gamma-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model. Diabetes Obes Metab. 2003;5:45-50.
40. Candido R, Jandeleit-Dahm KA, Cao Z, Nesteroff SP, Burns WC, Twigg SM, Dilley RJ, Cooper ME, Allen TJ. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation. 2002;106:246-253.
41. Tse J, Martin-McNaulty B, Halks-Miller M, Kauser K, DelVecchio V, Vergona R, Sullivan ME, Rubanyi GM. Accelerated atherosclerosis and premature calcified cartilaginous metaplasia in the aorta of diabetic male apo E knockout mice can be prevented by chronic treatment with 17 β-estradiol. Atherosclerosis. 1999;144:303-313.
42. Rosenman Y, Sapoznikov D, Mosseri M, Gilon D, Lotan C, Nassar H, Weiss, AT, Hasin Y, Gotsman MS. Long-term angiographic follow-up of coronary balloon angioplasty in patients with diabetes mellitus: a clue to the explanation of the results of the BARI study (Balloon Angioplasty Revascularization investigation). J Am Coll Cardiol. 1997;30: 1420-1425.
43. Abizaid A, Kornowski R, Mintz GS, Hong MK, Abizaid, AS, Mehran, R, Pichard AD, Kent KM, Statler LF, Wu H, Popma JJ, Leon MB. The influence of diabetes mellitus on acute and late clinical outcome following coronary stent implantation. J Am Coll Cardiol. 1998;32: 584-589.
44. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med 1996;335:217-225.
45. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R, RAVEL study group. Randomized study with the sirolimus-coated Bx velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions. N Engl J Med. 2002;346:1770-1771.
46. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL, Kuntz RE; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
47. Lemos PA, Saia F, Ligthart JM, Arampatzis CA, Sianos G, Tanabe K, Hoye A, Degertekin M, Daemen J, McFadden E, Hofma S, Smits PC, deFeyter P, van der Giessen WJ, van Domburg RT, Serruys PW. Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases. Circ. 2003;108:257-160.
48. Park SH, Marso SP, Zhou Z, Foroudi F, Topol EJ, Lincoff AM. Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus. Circulation. 2001;104:815-819.
49. Zhou Z, Wang K, Penn MS, Marso SP, Lauer MA, Forudi F, Zhou X, Qu W, Lu Y, Stern DM, Schmidt AM, Lincoff AM, Topol EJ. Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury. Circulation. 2003;107:2238-2243.
50. Roque M, Fallon JT, Badimon JJ, Zhang WX, Taubman MB, Reis ED. Mouse model of femoral artery denudation injury associated with the rapid accumulation of adhesion molecules on the luminal surface and recruitment of neutrophils. Arterioscler Thromb Vasc Biol. 2000;20: 335-342.
51. Sakaguchi T, Yan SF, Yan SD, Rong LL, Sousa M, Belov D, Andrassy M, Marso SP, Duda S, Arnold B, Liliensiek B, Nawroth PP, Stern DM, Schmidt AM, Naka, Y. Arterial restenosis: central role of RAGE-dependent neointimal expansion. J Clin Invest. 2003;111:959-972.
52. Phillips JW, Barringhaus KG, Sanders JM, Yang Z, Chen M, Hesselbacher S, Czarnik AC, Ley K, Nadler J, Sarembock IJ. Rosiglitazone reduces the accelerated neointima after arterial injury in a mouse injury model of type 2 diabetes. Circulation. 2003;108:1994-1999.
53. Min KM, Park SW, Cho KY, Song MS, Kim DK, Park GS, Lee MK. Troglitazone improves blood flow by inhibiting neointimal formation after balloon injury in Otsuka Long-Evans Tokushima fatty rats. Metabolism. 2002;51:998-1002.
54. Lin RY, Reis ED, Dore AT, Lu M, Ghodsi N, Fallon JT, Fisher EA, Vlassara H. Lowering of dietary advanced glycation end products (AGE) reduces neointimal formation after arterial injury in genetically hypercholesterolemic mice. Atherosclerosis. 2002;163:303-311.
55. Stephenson K, Tunstead J, Tsai A, Gordon R, Henderson S, Dansky HM. Neointimal formation after endovascular injury is markedly attenuated in db/db mice. Arterioscler Thromb Vasc Biol. 2003;23:2027-2033.
56. Oda A, Taniguchi T, Yokoyama M. Leptin stimulates rat aortic smooth muscle cell proliferation and migration. Kobe J Med Sci. 2001;47: 141-150.
57. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part I. Circulation. 2002;106:2734-2740.
58. Babapulle MN, Eisenberg MJ. Coated stents for the prevention of restenosis: Part II. Circulation. 2002;106:2859-2866.